XBIO | Xenetic Biosciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.25 - 4.63
52 Week Range	2.7800 - 5.20
Beta	2.90
Implied Volatility	547.29%
IV Rank	52.33%
Day's Volume	37,339
Average Volume	22,268
Shares Outstanding	1,542,140
Market Cap	6,939,630
Sector	Healthcare
Industry	Biotechnology
IPO Date	2016-06-30

Valuation
Profitability
Growth
Health
P/E Ratio	-1.69
Forward P/E Ratio	N/A
EPS	-2.66
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	4
Country	USA
Website	XBIO

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

XBIO's peers: DARE, RNAZ, VTGN, LABP, NEXI, ONCR, ZVSA, IMMX, PHIO, ATNF, NAVB, REVB, YS, GOVX, NBY, SONN, PALI, DRUG, VRAX, TNXP, ZURA, CYTO, ENVB, XTLB

*Chart delayed

Analyzing fundamentals for XBIO we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is on medium level and Health is frighteningly weak. For more detailed analysis please see XBIO Fundamentals page.

Watching at XBIO technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on XBIO Technicals page.